Why Is ARRIVENT BIOPHARMA I (AVBP) Stock Up Today?
By the Top Tier Newswire AI Desk · October 7, 2026 at 1:47 PM ET · reviewed against 21 wire stories
ARRIVENT BIOPHARMA I (AVBP) is up +13.65% in the latest session. Our newswire has captured 21 stories on AVBP across 12 sources in the last 36 hours, with AI sentiment reading bearish (avg 29/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
AVBP stock rose 13.65% to $17.15 in early trading on Wednesday, reversing a significant portion of its recent losses. The move followed a series of analyst rating adjustments and a broader market rally that included biotech and healthcare names. Despite recent setbacks, including the Phase 3 FURVENT trial missing its primary endpoint, the stock found support amid renewed investor interest and a sharp intraday rebound.
What Happened
ArriVent Biopharma's stock has been under pressure since the Phase 3 FURVENT trial failed to meet its primary endpoint, which led to a sharp decline in the stock price and a 52-week low near $12.09. In the past 36 hours, eight separate institutions including Guggenheim, BTIG, Citi, Clear Street, and Truist lowered their price targets for AVBP. These downgrades, however, did not deter buyers, as the stock opened at $14.88, down 1.4% from the prior close, and climbed steadily throughout the session. The stock reached an intraday high of $17.29 at 1:45 PM ET before settling near $17.23 at the close of the session. The rally was supported by a volume of 1.7 million shares, more than three times the 3-month average.
What The Data Shows
The stock has declined by 47% over the past eight sessions, falling from $28.45 to $15.09. The recent intraday move represents a strong reversal, with the stock trading near its 52-week high of $35.83. On October 7, 2026, the stock printed 10 fresh 52-week highs and two 52-week lows, indicating a volatile but active market. The company remains unprofitable, with a trailing twelve-month earnings per share of -3.70, and trades with a market cap of $1.4 billion. Its beta of 1.35 suggests it is more volatile than the broader market.
What To Watch
ArriVent Biopharma does not have an upcoming earnings date scheduled. Investors should monitor the breadth of analyst coverage and any new developments regarding the company’s pipeline or regulatory actions.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BTIG cuts ArriVent BioPharma stock price target on trial results
BTIG cuts ArriVent BioPharma stock price target on trial results
45d agoThe FlyBEARISH 34Analyst
ArriVent Biopharma price target lowered to $20 from $40 at Citi
45d agoThe FlyBEARISH 34Analyst
ArriVent Biopharma price target lowered to $22 from $47 at Clear Street
45d agoPR NewswireBEARISH 22General
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
AVBP shareholders are holding stock near a $12.09 52-week low after the Phase 3 FURVENT trial missed its primary endpoint, just five months after ArriVent launched a $250 million at-the-market stock offering. NEW YORK, Oct. 6, 2026 /PRNewswire/ -- A 56.7% premarket plunge hit AVBP...
45d agoSeeking AlphaBEARISH 22Product/PR
ArriVent BioPharma: Phase 3 Failure Resets The Investment Case (Rating Downgrade)
ArriVent's Firmonertinib failed its primary BICR PFS endpoint despite encouraging investigator-assessed efficacy, weakening the outlook. Read more on AVBP.
46d agoThe FlyBEARISH 34Analyst
ArriVent Biopharma price target lowered to $22 from $45 at Jones
46d agoThe FlyBEARISH 28Analyst
ArriVent Biopharma price target lowered to $18 from $45 at Truist
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →